Tadalafil for the treatment of pulmonary arterial hypertension

Expert Review of Respiratory Medicine

Volumn 5, Issue 3, 2011, Pages 315-328

  Klinger, James R ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

cGMP; natriuretic peptide; nitric oxide; phosphodiesterase inhibitor; phosphodiesterase type 5; primary pulmonary hypertension; pulmonary arterial hypertension; pulmonary hypertension treatment; tadalafil

Indexed keywords

AMBRISENTAN; BERAPROST; BOSENTAN; CICLETANINE; CYCLIC GMP; ENDOTHELIN RECEPTOR ANTAGONIST; ESCITALOPRAM; ILOPROST; IMATINIB; ITRACONAZOLE; KETOCONAZOLE; MACITENTAN; MILRINONE; NITRATE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; RIOCIGUAT; RITONAVIR; SELEXIPAG; SILDENAFIL; SITAXSENTAN; TADALAFIL; TEZOSENTAN; THEOPHYLLINE; TYVASO; UNCLASSIFIED DRUG; UNIPROST; VARDENAFIL;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BACKACHE; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DISEASE CLASSIFICATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EPISTAXIS; ERECTILE DYSFUNCTION; EXERCISE; FLUSHING; HUMAN; HYPERTRANSAMINASEMIA; INSOMNIA; ISCHEMIC OPTIC NEUROPATHY; LIMB PAIN; LUNG EMBOLISM; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MONOTHERAPY; MORBIDITY; MYALGIA; NONHUMAN; PROGNOSIS; PULMONARY HYPERTENSION; RECOMMENDED DRUG DOSE; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOSIS; TREATMENT RESPONSE; VISUAL DISORDER;

EID: 79959763101     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.11.38     Document Type: Article

References (90)

1. Simonneau G, Robbins IM, Beghetti M et al. Updated Clinical Classification of Pulmonary Hypertension. J. Am. Coll. Cardiol. 54, S43-S54 (2009
2. Thomson JR, Machado RD, Pauciulo MW et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-b family. J. Med. Genet. 37(10), 741-745 (2000
3. Machado RD, Pauciulo MW, Thomson JR et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am. J. Hum. Genet. 68(1), 92-102 (2001 (Pubitemid 32048364)
4. Harrison RE, Flanagan JA, Sankelo M et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J. Med. Genet. 40(12), 865-871 (2003 (Pubitemid 38117534)
5. Blanpain C, Le Poul E, Parma J et al. Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension. Cardiovasc. Res. 60(3), 518-528 (2003 (Pubitemid 37501109)
6. Humbert M. The burden of pulmonary hypertension. Eur. Respir. J. 30(1), 1-2 (2007 (Pubitemid 47073996)
7. D'Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 115(5), 343-349 (1991
8. Humbert M, Sitbon O, Chaouat A et al. Pulmonary arterial hypertension in France: results from a national registry. Am. J. Respir. Crit. Care Med. 173(9), 1023-1030 (2006
9. Badesch DB, Champion HC, Sanchez MA et al. Diagnosis and Assessment of Pulmonary Arterial Hypertension. J. Am. Coll. Cardiol. 54, S55-S66 (2009
10. Humbert M, Sitbon O, Chaouat A et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122(2), 156-163 (2010
11. Benza RL, Miller DP, Gomberg-Maitland M et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEALCirculation 122(2), 164-172 (2010).
12. Christman BW, McPherson CD, Newman JH et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. 327(2), 70-75 (1992
13. Weimann J, Ullrich R, Hromi J et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 92(6), 1702-1712 (2000 (Pubitemid 30412491)
14. Zhao L, Mason NA, Morrell NW et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104(4), 424-428 (2001 (Pubitemid 32678272)
15. Rubin LJ, Badesch D, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346, 896-903 (2002 (Pubitemid 34984638)
16. Galie N, Olschewski H, Oudiz RJ et al. Ambrisentan for the treatment of pulmonary arterial hypertension. Circulation 117, 3010-3019 (2008
17. Galie N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 353, 2148-2157 (2005 (Pubitemid 41653106)
18. Galie N, Brundage BH, Ghofrani HA et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 119, 2894-2903 (2009
19. Galié N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur. Heart J. 30(4), 394-403 (2009
20. Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 334(5), 296-302 (1996
21. Barst RJ, Gibbs JS, Ghofrani HA et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54(Suppl. 1), S78-S84 (2009
22. McLaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 119(16), 2250-2294 (2009
23. Humbert M, Barst RJ, Robbins IM et al. Combination of Bosentan with Epoprostenol in Pulmonary Arterial Hypertension: breathe-2. Eur. Respir. J. 24, 353-359 (2004 (Pubitemid 39232254)
24. Mclaughlin VV, Oudiz RJ, Frost A et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 174, 1257-1263 (2006 (Pubitemid 44924827)
25. Mclaughlin VV, Benza RL, Rubin LJ et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J. Am. Coll. Cardiol. 55, 1915-1922 (2010
26. Seyfarth HJ, Pankau H, Hammerschmidt S, Schauer J, Wirtz H, Winkler J. Bosentan improves exercise tolerance and tei index in patients with pulmonary hypertension and prostanoid therapy. Chest 128, 709-713 (2005 (Pubitemid 41140500)
27. Simonneau G, Rubin LJ, Galie N et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann. Intern. Med. 149, 521-530 (2008
28. Koller KJ, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation 86(4), 1081-1088 (1992
29. Pandey KN. Biology of natriuretic peptides and their receptors. Peptides 26(6), 901-932 (2005 (Pubitemid 40725366)
30. Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3́:5́-cyclic monophosphate levels in various tissue preparations. Proc. Natl. Acad. Sci. USA 74(8), 3203-3207 (1977 (Pubitemid 8180317)
31. Klinger JR. The nitric oxide/cGMP signaling pathway in pulmonary hypertension. Clin. Chest Med. 28(1), 143-167 (2007 (Pubitemid 46343758)
32. Frostell CG, Blomqvist H, Hedenstierna G, Lundberg J, Zapol WM. Inhaled nitric oxide selectively reverses human hypoxic pulmonary vasoconstriction without causing systemic vasodilation. Anesthesiology 78(3), 427-435 (1993 (Pubitemid 23090476)
33. Wanstall JC, Hughes IE, O'Donnell SR. Evidence that nitric oxide from the endothelium attenuates inherent tone in isolated pulmonary arteries from rats with hypoxic pulmonary hypertension. Br. J. Pharmacol. 114(1), 109-114 (1995
34. Hill NS, Klinger JR, Warburton RR, Pietras L, Wrenn DS. Brain natriuretic peptide: possible role in the modulation of hypoxic pulmonary hypertension. Am. J. Physiol. 266(3 Pt 1), L308-L315 (1994
35. Klinger JR, Warburton RR, Pietras L et al. Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy. Am. J. Physiol. Heart Circulation Physiol. 282(1), H58-H65 (2002 (Pubitemid 34654134)
36. Zhao L, Long L, Morrell NW, Wilkins MR. NPR-A-Deficient mice show increased susceptibility to hypoxia-induced pulmonary hypertension. Circulation 99(5), 605-607 (1999 (Pubitemid 29077357)
37. Charloux A, Chaouat A, Piquard F, Brandenberger G, Weitzenblum E, Geny B. Renal hyporesponsiveness to brain natriuretic peptide: both generation and renal activity of cGMP are decreased in patients with pulmonary hypertension. Peptides 27(11), 2993-2999 (2006 (Pubitemid 44584406)
38. Kharitonov SA, Cailes JB, Black CM, du Bois RM, Barnes PJ. Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax 52(12), 1051-1055 (1997 (Pubitemid 27515784)
39. Francis SH, Blount MA, Zoraghi R, Corbin JD. Molecular properties of mammalian proteins that interact with cGMP: protein kinases, cation channels, phosphodiesterases, and multi-drug anion transporters. Front. Biosci. 10, 2097-2117 (2005 (Pubitemid 40908915)
40. Kass DA, Champion HC, Beavo JA. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circulation Res. 101(11), 1084-1095 (2007 (Pubitemid 350146434)
41. Lincoln TM, Dey N, Sellak H. Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J. Appl. Physiol. 91, 1421-1430 (2001). (Pubitemid 32803941)
42. Corbin JD, Turko IV, Beasley A, Francis SH. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur. J. Biochem. 267, 2760-2767 (2000 (Pubitemid 30304274)
43. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol. Ther. 109(3), 366-398 (2006 (Pubitemid 43132818)
44. Keravis T, Lugnier C. Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs. Curr. Pharm. Des. 16(9), 1114-1125 (2010
45. Ghofrani HA, Voswinckel R, Reichenberger F et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J. Am. Coll. Cardiol. 44(7), 1488-1496 (2004 (Pubitemid 39303954)
46. Giordano D, De Stefano ME, Citro G, Modica A, Giorgi M. Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE-5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochim. Biophys. Acta. 1539, 16-27 (2001 (Pubitemid 32522866)
47. Maclean MR, Johnston ED, Mcculloch KM, Pooley L, Houslay MD, Sweeney G. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J. Pharmacol. Exp. Ther. 283(2), 619-624 (1997 (Pubitemid 27514618)
48. Hanson KA, Ziegler JW, Rybalkin SD, Miller JW, Abman SH, Clarke WR. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am. J. Physiol. 275, L931-L941 (1998
49. Mikhail GW, Prasad SK, Li W et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur. Heart J. 25, 431-436 (2004 (Pubitemid 38391526)
50. Ghofrani HA, Pepke-Zaba J, Barbera JA et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43, 68S-72S (2004 (Pubitemid 38759720)
51. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105(20), 2398-2403 (2002 (Pubitemid 34556392)
52. Richalet JP, Gratadour P, Robach P et al. Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. Am. J. Respir. Crit. Care Med. 171(3), 275-281 (2005
53. Preston IR, Hill NS, Gambardella LS, Warburton RR, Klinger JR. Synergistic effects of ANP and sildenafil on cGMP levels and amelioration of acute hypoxic pulmonary hypertension. Exp. Biol. Med. 229(9), 920-925 (2004 (Pubitemid 39539377)
54. Klinger JR, Thaker S, Houtchens J, Preston IR, Hill NS, Farber HW. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest 129(2), 417-425 (2006 (Pubitemid 43289864)
55. Steiner MK, Preston IR, Klinger JR, Hill NS. Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides. Curr. Opin. Pharmacol. 5(3), 245-250 (2005 (Pubitemid 40674246)
56. Angulo J, Gadau M, Fernandez A et al. IC351 enhances nitric oxide-mediated relaxation of human arterial and trabecular penile smooth muscle. Diabetologia 44(S1), A295 (2001
57. Marmor MF, Kessler R. Sildenafil (Viagra) and ophthalmology. Surv. Ophthalmol. 44(2), 153-162 (1999
58. Adcirca™, package insert. Eli Lilley and company, IN, USA.
59. Maw GN, Allerton CM, Gbekor E, Million WA. Design, synthesis and biological activity of b-carboline-based type-5 phosphodiesterase inhibitors. Bioorg. Med. Chem. Lett. 13(8), 1425-1428 (2003 (Pubitemid 36369181)
60. Wayman C, Phillips S, Lunny C et al. Phosphodiesterase 11 (PDE-11) regulation of spermatozoa physiology. Int. J. Impot. Res. 17(3), 216-223 (2005 (Pubitemid 40675501)
61. Forgue ST, Patterson BE, Bedding AW et al. Tadalafil pharmacokinetics in healthy subjects. Br. J. Clin. Pharmacol. 61(3), 280-288 (2006 (Pubitemid 43382627)
62. Skoumal R, Chen J, Kula K et al. Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. Eur. Urol. 46(3), 362-369 (2004 (Pubitemid 39078572)
63. Tolrá JR, Campaña JM, Ciutat LF, Miranda EF. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J. Sex Med. 3(5), 901-909 (2006 (Pubitemid 44269546)
64. Schermuly RT, Kreisselmeier KP, Ghofrani HA et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 169(1), 39-45 (2004 (Pubitemid 38233887)
65. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N. Engl. J. Med. 343(18), 1342 (2000
66. Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 84(2), E4 (2000
67. Singh B, Gupta R, Punj V et al. Sildenafil in the management of primary pulmonary hypertension. Indian Heart J. 54(3), 297-300 (2002 (Pubitemid 34987816)
68. Ghofrani HA, Wiedemann R, Rose F et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360(9337), 895-900 (2002 (Pubitemid 35283832)
69. Ghofrani HA, Schermuly RT, Rose F et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 167(8), 1139-1141 (2003 (Pubitemid 36459662)
70. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J. Am. Coll. Cardiol. 43(7), 1149-1153 (2004 (Pubitemid 38452588)
71. Palmieri EA, Affuso F, Fazio S, Lembo D. Tadalafil in primary pulmonary arterial hypertension. Ann. Intern. Med. 141(9), 743-744 (2004 (Pubitemid 39434855)
72. Mukhopadhyay S, Sharma M, Ramakrishnan S et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation 114(17), 1807-1810 (2006 (Pubitemid 44673355)
73. Aggarwal P, Patial RK, Negi PC, Marwaha R. Oral tadalafil in pulmonary artery hypertension: a prospective study. Indian Heart J. 59(4), 329-335 (2007
74. Bharani A, Patel A, Saraf J, Jain A, Mehrotra S, Lunia B. Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension. Indian Heart J. 59(4), 323-328 (2007).
75. Berger RM, Bonnet D. Treatment options for paediatric pulmonary arterial hypertension. Eur. Respir. Rev. 19(118), 321-330 (2010
76. Barst RJ, Ertel SI, Beghetti M, Ivy DD. Pulmonary arterial hypertension: a comparison between children and adults. Eur. Respir. J. 37(3), 665-677 (2011
77. Arneson C, McDevitt S, Klinger JR. Tadalafil in geriatric patients with pulmonary arterial hypertension. Chest 138, 367A (2010
78. Chen HC, Wang CS, Chuang SH, Wang CY. Pulmonary embolism after tadalafil ingestion. Pharm. World Sci. 30(5), 610-612 (2008
79. Tripathi A, O'Donnell NP. Branch retinal artery occlusion; another complication of sildenafil. Br. J. Ophthalmol. 84(8), 934-935 (2000 (Pubitemid 30599114)
80. Akash R, Hrishikesh D, Amith P, Sabah S. Case report: association of combined nonarteritic anterior ischemic optic neuropathy (NAION) and obstruction of cilioretinal artery with overdose of Viagra. J. Ocul. Pharmacol. Ther. 21(4), 315-317 (2005 (Pubitemid 41192902)
81. Peter NM, Singh MV, Fox PD. Tadalafil-associated anterior ischaemic optic neuropathy. Eye (Lond.) 19(6), 715-717 (2005 (Pubitemid 40895504)
82. Bollinger K, Lee MS. Recurrent visual field defect and ischemic optic neuropathy associated with tadalafil rechallenge. Arch. Ophthalmol. 123(3), 400-401 (2005 (Pubitemid 41007591)
83. McKoy JM, Bolden CR, Samaras A, Raisch DW, Chandler K, Bennett CL. Sildenafil-and tadalafil-associated optic neuropathy: implications for men after prostate cancer treatment. Community Oncol. 6(2), 78-80 (2009
84. Laties AM. Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date. Drug Safety 32(1), 1-18 (2009
85. Wilkins MR, Paul GA, Strange JW et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am. J. Respir. Crit. Care Med. 171(11), 1292-1297 (2005 (Pubitemid 40740738)
86. Berman RE, Arneson C, Golden G. Relationship between dosing and common adverse events with tadalafil in patients with pulmonary arterial hypertension. Chest 138, 352A (2010
87. Ghofrani HA, Wiedemann R, Rose F et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann. Intern. Med. 136, 515-522 (2002 (Pubitemid 34252285)
88. Ghofrani HA, Rose F, Schermuly RT et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol. 42(1), 158-164 (2003 (Pubitemid 36760778)
89. Wrishko RE, Dingemanse J, Yu A, Darstein C, Phillips DL, Mitchell MI. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J. Clin. Pharmacol. 48(5), 610-618 (2008 (Pubitemid 351503516)
90. Spence R, Mandagere A, Harrison B, Dufton C, Boinpally R. No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. J. Pharm. Sci. 98(12), 4962-4974 (2009).